Share “News Summary: Pfizer rheumatoid arthritis...”

News Summary: Pfizer rheumatoid arthritis drug

Associated Press Modified: November 6, 2012 at 5:19 pm •  Published: November 6, 2012
Advertisement

APPROVAL: Pfizer Inc. says the Food and Drug Administration approved its rheumatoid arthritis drug Xeljanz, a twice-per-day pill.

WHO IT'S FOR: Xeljanz is designed to slow the progression of moderate to severe rheumatoid arthritis. It is approved for patients who either cannot take methotrexate, a standard treatment for the disease, or haven't been helped by it. Xeljanz interferes with enzymes that contribute to tissue inflammation.

THE BIG PICTURE: Rheumatoid arthritis is a major area of research for drug companies because it is a chronic condition, meaning patients will likely take the drugs regularly for a long time.


AROUND THE WEB

  1. 1
    OKC man arrested after allegedly trying to set up meeting to have sex with minor
  2. 2
    Hoping to become tourist haunt, Nevada town finds boost in spirits
  3. 3
    Violence not keeping away Americans: Mexico sees 25% spike in U.S. travelers
  4. 4
    Jimmy Carter: U.S. Is an 'Oligarchy With Unlimited Political Bribery'
  5. 5
    'Voice of the Cowboys' Larry Reece says he's cancer free
+ show more

FEATURED JOBS



× Trending business Article